businesspress24.com - Immunotec Announces Financial Results for the Third Quarter Ended July 31, 2011 and Changes to its B
 

Immunotec Announces Financial Results for the Third Quarter Ended July 31, 2011 and Changes to its Board

ID: 1037746

Network's sales in Mexico up by 320% and Adjusted EBITDA of $325 thousand

(firmenpresse) - VAUDREUIL-DORION, QUEBEC -- (Marketwire) -- 09/09/11 -- Immunotec Inc. (TSX VENTURE: IMM), a Canadian based company and a leader in the wellness industry (the "Company"), today reported financial results for the third quarter of fiscal year 2011.

"We are very pleased with our overall performance" said Robert Henry, Immunotec's Executive Chairman and CEO; "We remain confident and focus on growing our markets despite a difficult worldwide economic climate".

At yesterday`s meeting, the Board of Directors announced the resignation of Mr. Jean La Couture, Director and Chairman of the Audit Committee to be effective September 30, 2011. The Board of Directors also approved the nomination of Mr. Rod Budd for this role starting on October 1, 2011 and the nomination of Mr. Charles Orr as lead Director. Mr. Orr has been a Director of the Company since 2006.

On behalf of the Immunotec Board of Directors "We want to thank Jean for his five years of service on Immunotec's Board. Jean has been a valuable contributor to the Company. We acknowledge the work he did during the CEO transition.

"We are pleased to welcome Rod. His business experience through 25 years of partnership at Ernst & Young will be of great value to our Company." said Robert Henry, Immunotec's Executive Chairman and CEO.

On September 8, 2011 the Board of Directors approved two grants of options. One for Mr. Henry which entitles him to acquire up to 500,000 common shares of the Company and the other one to Mr. Orr which entitles him to acquire up to 25,000 common shares of the Company. Both grants will have an exercise price of $0.24 per share, representing a premium over $0.17, being the closing price of the Company's Shares on the TSX-Venture Exchange on September 7th, 2011 the trading day preceding the grant.

Highlights for Q3

About Immunotec Inc.

Immunotec is a world class business opportunity supported by unique scientifically proven products that improve wellness. Headquartered with manufacturing facilities near Montreal, Canada, the Company also has distribution capacities to support its commercial activities in Canada and internationally to the United States, Europe, Mexico and The Caribbean.





The Company files its consolidated financial statements, its management and discussion analysis report, its press releases and such other required documents on the SEDAR database at and on the Company's website at . The common shares of the Company are listed on the TSX Venture Exchange under the ticker symbol IMM.

The TSX Venture does not accept responsibility for the adequacy or accuracy of this release.



Contacts:
Patrick Montpetit
VP and Chief Financial Officer
(450) 510-4527


Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  EnteroMedics Announces Presentation of Maestro(R) RC System Clinical Data at the XVI World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders
Spine Centers of America Endoscopic Spine Surgery Ends Back Pain for NJ Car Accident Victim
Bereitgestellt von Benutzer: MARKET WIRE
Datum: 09.09.2011 - 15:27 Uhr
Sprache: Deutsch
News-ID 1037746
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

VAUDREUIL-DORION, QUEBEC


Phone:

Kategorie:

Health & Nutrition


Anmerkungen:


Diese Pressemitteilung wurde bisher 184 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Immunotec Announces Financial Results for the Third Quarter Ended July 31, 2011 and Changes to its Board
"
steht unter der journalistisch-redaktionellen Verantwortung von

Immunotec Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Immunotec Inc.



 

Who is online

All members: 10 562
Register today: 1
Register yesterday: 2
Members online: 0
Guests online: 82


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.